Compare Dolby Laboratories, Inc. (DLB) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Morgan Stanley — how do they compare? Dolby Laboratories, Inc. trades at $58.45 (market cap $5.47B), while Morgan Stanley trades at $188.6 (market cap $297.95B). The key difference: Morgan Stanley is far larger — about 54.5× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Morgan Stanley for 93 Days on average.
| DLB | MS | |
|---|---|---|
Market Cap | $5.47B | $297.95B |
Volume | 691,016 | 5,030,247 |
Sector | Technology | Financials |
52-Week High | $70.09 | $228.42 |
52-Week Low | $48.51 | $151.86 |
Typical Hold Time | 98 Days | 93 Days |
Enterprise Value | $4.84B | $663.67B |
Dividend Yield | 2.47% | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.35, down 0.19% with bearish technical signals despite strong profitability margins. The company maintains robust fundamentals with 87.61% gross margins and consistent earnings beats, though revenue has plateaued around $1.3B. Recent leadership transition to Marc Whitten and expanded Meta partnership for Dolby Atmos/Vision represent key developments. Technical indicators show resistance at $59 with support at $58.
DLB offers stable cash flow generation and dividend income but faces growth challenges with flat revenue. Analyst consensus targets $90.33 (55% upside) with 47% buy ratings, though near-term execution risks and licensing volatility warrant caution. The stock presents value for income investors but requires revenue acceleration for significant appreciation.
Morgan Stanley (MS) trades at $187.41, down 1.86% on the day, with a bearish technical signal but strong fundamentals including a P/E of 15.32 and net income margin of 27.59%. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $50.2B in 2022 to $66.0B in 2025, and the company highlights growth opportunities in wealth management and AI financing.
The outlook is supported by a bullish analyst consensus with a $229.25 price target, though risks include volatile cash flows and rising debt-to-asset ratios. Near-term price action is testing support near $184, with investor sentiment mixed amid fading capital markets momentum but positive long-term growth narratives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
